Integrated Microfluidic Systems for Diagnosis of Periprosthetic Joint Infection

NCT04056780 | Unknown

• 1 other identifier: 201802127B0
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

Diagnosing periprosthetic joint infection (PJI) remains a major clinical challenge. The diagnosis of PJI is based on a composition of clinical judgment, serologic test from peripheral blood, synovial fluid cytology and biomarkers, radiography, microbiology, histopathologic evaluation of periprosthetic tissue, and intraoperative findings. The importance of PJI diagnosis give the subsequent treatment options, like the removal of prosthesis, debridement and prosthesis retention and the time of reimplantation. Currently, The Second International Consensus Meeting (ICM) has announced its criteria for the diagnosis of PJI. The preoperative diagnosis includes serologic tests (C-reactive protein, D-dimer, and erythrocyte sedimentation rate) and synovial fluid biomarkers (white blood cell and differential, leukocyte esterase and ⍺-defensin). The intraoperative diagnosis includes a single positive culture, positive histology, and positive intraoperative purulence. However, some of the markers used in the 2018 ICM criteria, such as ⍺-defensin, leukocyte esterase, and synovial fluid C-reactive protein, are not available in every hospital and cannot be immediately available to clinicians in decision making. The microfluidic technologies have made a notable impact on the evolution of diagnostic tools by providing a rapid and cost-effective platform for the application of immunoassay techniques. The microfluidic system integrates the complex processing steps of the laboratory protocols into a single chip through logical integration and optimization of processes. Chang Gung Memorial Hospital and National Tsing Hua University have conducted preliminary research to confirm the feasibility of their microfluidic systems. Therefore, the project will develop a "microfluidic biomarker detection chip" to detect the concentrations three important biomarkers for PJI, including ⍺-defensin, leukocyte esterase and C-reactive protein in synovial fluids. This will be a three-year project. In the 1st year, 50 patients who will be scheduled to undergo unilateral revision total joint arthroplasty (RTJA) will be collected with the synovial fluid and tested on a laboratory platform. In the 2nd year, based on laboratory results, 50 patients undergoing RTJAs will be recruited to develop a microfluidic chip system, and their on-chip performance will be fine-tuned and optimized. In the 3rd year, 50 patients undergoing RTJA will be collected, and the verification of the microfluidic system will be realized. This system will be validated in PJIs cohorts in the first stage of debridement and implant removal, in the interim period, and the second stage of reimplantation. It is expected that biomarker detection chip will improve medical distress and bring important information to clinical decision-making.

Conditions

Prosthetic Joint Infection

Outcome Measures

Primary Outcomes (3)

• The value of synovial fluid human ⍺-defensin 1-3 (HNP1-3)

  To test synovial fluid ⍺-defensin

  Post-operative period after collect per 40 cases (usually within 180-365 days following surgery)

• The value of leukocyte esterase (LE)

  To test synovial fluid LE

  Immediate post-operative period (usually within 1-2 days following surgery)

• The value of synovial C-reactive protein (CRP)

  To test synovial fluid CRP

  Immediate post-operative period (usually within 1-2 days following surgery)

Study Arms (2)

Septic group

The septic group will be considered as patients that fulfill the 2018 ICM definition of PJI.

Other: Sample collection study

Aseptic group

The aseptic group will be considered as patients that don't fulfill the 2018 ICM definition of PJI.

Other: Sample collection study

Interventions

Sample collection study OTHER

Sample collection and collection of laboratory values

Aseptic group; Septic group

Eligibility Criteria

• Age: 20 Years - 90 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Given the lack of published data regarding the application of 2nd ICM criteria, we will not perform a power analysis for sample size calculation before the study. All consecutive patients undergoing revision total joint arthroplasty (hips and knees) will be eligible for recruitment.

You may qualify if:

• Revision total knee arthroplasty
• Revision total hip arthroplasty
• Sufficiently annotated clinical and laboratory data for classification by the 2018 ICM criteria for PJI
• Sufficient synovial fluid for study methods.

You may not qualify if:

• Inadequate synovial fluid for analysis
• Adverse local tissue reaction (ALTR)
• Crystalline deposition arthropathy
• Inflammatory arthropathy flare

Sponsors & Collaborators

• Chang Gung Memorial Hospital: lead

Study Sites (1)

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, 833, Taiwan

Location

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 11, 2019
• First Posted: August 14, 2019
• Study Start: April 1, 2020
• Primary Completion: March 31, 2022
• Study Completion: May 31, 2022
• Last Updated: August 3, 2021

Record last verified: 2021-07

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1)